RhumbLine Advisers
AEGR

RhumbLine Advisers’s Aegerion Pharmaceuticals AEGR Stock Holding History

RhumbLine Advisers’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-26,314
Closed -$97K – 3070
2016
Q1 		$97K Buy
26,314
+100
+0.4% +$619 ﹤0.01% 2900
2015
Q4 		$265K Buy
26,214
+1,465
+6% +$17.6K ﹤0.01% 2651
2015
Q3 		$337K Buy
24,749
+111
+0.5% +$1.98K ﹤0.01% 2467
2015
Q2 		$467K Sell
24,638
-4,875
-17% -$106K ﹤0.01% 2379
2015
Q1 		$772K Buy
29,513
+4,000
+16% +$102K ﹤0.01% 2026
2014
Q4 		$534K Sell
25,513
-2,150
-8% -$54.2K ﹤0.01% 2237
2014
Q3 		$923K Sell
27,663
-310
-1% -$9.62K ﹤0.01% 1810
2014
Q2 		$898K Sell
27,973
-841
-3% -$31.3K ﹤0.01% 1899
2014
Q1 		$1.33M Sell
28,814
-1,410
-5% -$82.7K ﹤0.01% 1615
2013
Q4 		$2.15M Sell
30,224
-430
-1% -$32.9K 0.01% 1325
2013
Q3 		$2.63M Buy
30,654
+1,152
+4% +$97.6K 0.01% 1174
2013
Q2 		$1.87M Buy
+29,502
New +$1.57M 0.01% 1347

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RhumbLine Advisers's AEGR Position: Q2 2016 in Review

RhumbLine Advisers sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 26,314 shares — an estimated $97K sold.

RhumbLine Advisers first reported a position in AEGR in Q2 2013 and held it in 12 quarters. The position peaked at $2.63M in Q3 2013. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • RhumbLine Advisers reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • RhumbLine Advisers sold 26,314 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $97K.
  • RhumbLine Advisers first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 12 quarters.
  • RhumbLine Advisers's Aegerion Pharmaceuticals position peaked at $2.63M in Q3 2013.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on RhumbLine Advisers's 13F filing for Q2 2016, filed 11 Aug 2016.